Clinical Ink Acquires Digital Artefacts


Clinical Ink, a global clinical trial data and technology company, has announced its acquisition of Digital Artefacts, a digital endpoint-based technology company with a modular platform for complex cognitive, behavioral, and physiological data capture.

The combination of Clinical Ink and Digital Artefacts will provide benefits including:

  • Scientifically validated neurocognitive assessment and research tools (50+ modular, self-administered assessments)
  • Combination of standardized eCOA scales/assessments with digital endpoints to produce quantitative patient outcomes
  • Trial specific remote active and passive behavioral assessment, including wearable and sensor data
  • Precision Real-World Data and insights across complex therapeutic areas for which cognition is an endpoint
  • Scaled delivery capabilities in logistics, helpdesk, project management, and device acquisition/support for DCTs

Clinical Ink Acquires Digital Artefacts

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.